Author: Editor

Drs. Jack West, Charu Aggarwal, and Benjamin Levy recently gathered to review top discussion points for Lung Cancer from ASCO 2019. In this video, the doctors discuss long term outcomes with Pembrolizumab. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Sarmad Sadeghi, MD of USC Norris Comprehensive Cancer Center explains awaiting approval from the FDA in bladder and prostate cancer.

Sarmad Sadeghi, MD of USC Norris Comprehensive Cancer Center explains the role of nephrectomy is getting smaller and smaller in kidney cancer.

John Fruehauf, MD disucsses whether the CheckMate 204 data will affect treatment selection in brain metastases

John Fruehauf, MD of UC Irvine Health discusses new first-line therapy for asymptomatic melanoma brain metastases.         new first-line therapy, asymptomatic melanoma brain metastases, uc irvine health, checkmate 204 study, study, checkmate 204

John Fruehauf, MD of UC Irvine Health explains clinicians could change the way they manage their patients by lowering doses and possibly impacting treatment that way.

John Fruehauf, MD provides insight on how to address toxicity that is causing colitis.

John Fruehauf, MD of UC Irvine Health discusses lowering toxicity through alternate dosing.

John Fruehauf, MD of UC Irvine Health presents whether data practice will change for clinicians.

John Fruehauf, MD of UC Irvine Health explains how INMC data has impacted surgical oncologists.

John Fruehauf, MD of UC Irvine Health discusses IMNC (International Neoadjuvant Melanoma Consoritum) Abstract 9503.

Afsaneh Barzi, MD of Keck School of Medicine discusses the factors to consider in the IDEA collaboration.

Afsaneh Barzi, MD of Keck School of Medicine provides the impact the IDEA data will have on clinicians.

Afsaneh Barzi, MD of Keck School of Medicine explains IDEA collaboration findings in 3 versus 6 months for stage 3 colon cancer.

Afsaneh Barzi, MD of Keck School of Medicine presents the IDEA (International Duration Evaluation of Adjuvant Chemotherapy) collaboration which investigated the adjuvant oxaliplatin-based therapy for patients with high-risk stage II colorectal cancer.

Afsaneh Barzi, MD of Keck School of Medicine discusses the immediate implications in the POLO trial is mandatory germline testing for all patients with pancreatic cancer.

Afsaneh Barzi, MD of Norris Cancer Center provides insight on the still unanswered questions in the POLO study.

Afsaneh Barzi, MD of Norris Cancer Center explains the phase III POLO trial, a maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer.

Philadelphia, PA (August 26, 2019) – Oncoceutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for ONC206, allowing the first-in-human trial of the compound. ONC206 is the first of the family of drug candidates, which we call “imipridones”, that possess the same core chemical structure as ONC201. The first clinical trial for ONC206 in adults with primary central nervous system neoplasms will be conducted at the National Cancer Institute (NCI) under the leadership of Mark Gilbert, MD, Chief of the Neuro-Oncology Branch, Center for Cancer Research (CCR) and Brett Theeler,…

Jacob Sands, MD explica lurbinectedin presentado en ASCO 2019.

Jacob Sands, MD discusses lurbinectedin providing another treatment option for patients and practitioners.

Jacob Sands, MD discusses lurbinectedin presented at ASCO 2019.

Jacob Sands, MD provides data and updates on lurbinectedin in small cell lung cancer immunotherapy treatment.

Pascal Besman, COO Pharmamar – PharmaMar to submit New Drug Application (NDA) for lurbinectedin under accelerated approval in SCLC in the USA. Pascal Besman, Pharmamar COO discusses advantages and potential limitations of the new drug.

HATFIELD, Pa. and CLEVELAND, Aug. 27, 2019 /PRNewswire/ — Genisphere LLC and University Hospitals Cleveland Medical Center announced a partnership to study and develop unique strategies to treat pancreatic cancer. According to their agreement, investigators will optimize 3DNA®-based therapeutics designed to target and kill pancreatic tumors. Projects will include delivering a variety of therapeutic cargos, including small molecules and siRNA, formulated with pancreatic tumor-targeting molecules on Genisphere’s 3DNA® nanocarrier. Jordan Winter, MD, Chief of the Division of Surgical Oncology at University Hospitals Cleveland Medical Center and Director of Surgical Services at UH Seidman Cancer Center, is the lead researcher on…

Lurbinectedin, a potential practice changing drug if approved, will be the only agent available in SCLC tested with immunotherapy. PharmaMar to submit New Drug Application (NDA) for lurbinectedin under accelerated approval in SCLC in the USA.         lurbinectedin, potential practice changing drug, new drug application (nda), nda, pharmamar, immunotherapy, sclc

PharmaMar to submit New Drug Application (NDA) for lurbinectedin under accelerated approval in SCLC in the USA. Hossein Borghaei, MD discusses the recent data released and advantages and potential limitations of the new drug.

Niraparib demonstrated clinically relevant activity among women with heavily pretreated ovarian cancer, particularly those with homologous recombination deficiency-positive, platinum-sensitive disease, according to findings from the phase 2 QUADRA study published in The Lancet Oncology. The results, which also showed no new safety signals, support extending the use of poly(ADP-ribose) polymerase (PARP) inhibitors to a wider population of women with late-line ovarian cancer, including those without BRCAmutations, according to the researchers. “This is another piece of the puzzle that helps our patients live longer,” Kathleen Moore, MD, associate director of clinical research at Stephenson Cancer Center at University of Oklahoma College of Medicine, said in a press…

Jack Stewart, CSO of Soricimed Biopharma explains SOR-C13 is the leading drug in a phase 1b clinical trial in late stage pancreatic cancer.

Jack Stewart, CSO of Soricimed Biopharma discusses SOR-C13, a selective inhibitor of TRPV6, binds with affinity and disrupts how TRPV6 functions.

Jack Stewart, CSO of Soricimed Biopharma explains SOR-C13 potentially shows promise in ovarian, metastatic prostate and pancreatic cancer.

Data from largest population study to date help identify at-risk individuals, could inform screening initiatives Published on: August 08, 2019 (WASHINGTON, August 8, 2019) — New data suggest that people who have a parent, sibling, or child with blood cancer have a higher likelihood of being diagnosed with the disease. The study published online today in Blood offers the first evidence that such familial risks exist across the spectrum of hematologic malignancies. Age of diagnosis, whether the relative is a parent, sibling, or child, and the number of affected first-degree relatives play a defining role in the relative risk of developing certain blood cancers, according to the study. “This information improves our understanding of the causes of – and potential inherited predisposition to – blood cancers and should inform the identification and characterization of genetic risk factors for blood cancer, as well as how we best clinically…

Findings may guide decisions about which patients will benefit most from treatment with sorafenib Advanced hepatocellular carcinoma (HCC) is commonly treated with sorafenib Subset of CD8+ cells are biomarker linked with survival benefit, team shows Evidence could lead to more individualized treatments for liver cancer patients  BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center immunology researchers have uncovered a biomarker that may help explain why some patients respond better than others to a common chemotherapy treatment for liver cancer. They hope that their analysis of immune responses among patients receiving sorafenib can lead to more individualized treatment options and better…

TAGRISSO is the only medicine demonstrating statistically-significant overall survival benefit in this setting. Also increased the time patients with central nervous system metastases lived without disease progression   (WILMINGTON, Del., August 9, 2019) AstraZeneca today announced positive overall survival (OS) results from the Phase III FLAURA trial, a randomized, double-blinded, multicenter trial of TAGRISSO in previously-untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) mutations.   TAGRISSO showed a statistically-significant and clinically-meaningful improvement in OS, a secondary endpoint in the FLAURA Phase III trial, compared with erlotinib or gefitinib both of which were previous standard-of-care (SoC) treatments…

Adjuvant chemoradiotherapy improved overall survival for women with locally advanced endometrial cancer compared with radiation alone, a post-hoc analysis of the phase III PORTEC-3 trial found. With adjustment for stratification factors, overall survival (OS) at 5 years was 81.4% in the chemoradiotherapy group compared with 76.1% in the group receiving radiotherapy alone (adjusted HR 0.70, 95% CI 0.51-0.97, P=0.034), reported Stephanie de Boer, MD, of Leiden University Medical Center in the Netherlands, and colleagues.   And in their study of over 600 patients with stage I-III endometrial cancer, failure-free survival (FFS) at 5 years was 76.5% with chemoradiotherapy versus 69.1% with…

NEW YORK — While new drugs for cancer are helping patients fight the disease, they also produce side effects that can affect the hair, skin and nails and can significantly affect quality of life and, potentially, the ability to continue treatment, according to a press release issued here at the American Academy of Dermatology Summer Meeting. “Approximately half of patients who undergo immunotherapy and receive targeted cancer medications experience a skin-related reaction to the medication,” Anisha Patel, MD, FAAD, an associate professor of dermatology and internal medicine at the University of Texas MD Anderson Cancer Center in Houston, said in the…

Niraparib demonstrated clinically relevant activity among women with heavily pretreated ovarian cancer, particularly those with homologous recombination deficiency-positive, platinum-sensitive disease, according to findings from the phase 2 QUADRA study published in The Lancet Oncology. The results, which also showed no new safety signals, support extending the use of poly(ADP-ribose) polymerase (PARP) inhibitors to a wider population of women with late-line ovarian cancer, including those without BRCAmutations, according to the researchers. “This is another piece of the puzzle that helps our patients live longer,” Kathleen Moore, MD, associate director of clinical research at Stephenson Cancer Center at University of Oklahoma College of Medicine, said in a press…

TORONTO, CANADA / ACCESSWIRE / AUGUST 6, 2019 / Soricimed Biopharma Inc. (“Soricimed”), a clinical-stage pharmaceutical company developing first-in-class, targeted cancer therapeutics, announced today that The University of Texas MD Anderson Cancer Center (MDACC) has activated an Investigator Initiated Clinical trial of Soricimed’s lead drug candidate, SOR-C13 in late stage pancreatic cancer. This trial was initiated by Siqing Fu, MD PhD, a member of the Department of Investigational Cancer Therapeutics at MDACC, one of the world’s most respected cancer research centers, based on the results of Soricimed’s multi-center Phase 1 clinical trial in patients with late-stage solid tumor cancer. The Phase 1 trial…

– Milestone represents the first patient dosed with UltraCAR-T targeting solid tumors – First-in-class investigational therapy using autologous CAR-T cells targeting advanced, recurrent platinum resistant ovarian, fallopian tube or primary peritoneal cancer GERMANTOWN, Md., Aug. 5, 2019 /PRNewswire/ – Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the first patient has been dosed with Precigen’s PRGN-3005, a first-in-class investigational therapy using Precigen’s UltraCAR-Tâ„¢ therapeutic platform. PRGN-3005 UltraCAR-T is an autologous chimeric antigen receptor T (CAR-T) cell…

— Enhanced survival outcomes in DKK1-high gastroesophageal junction and gastric cancer patients – — DKK1-high biomarker enables future patient selection – — Live conference call and webcast with clinical investigators at 8:30 AM ET — CAMBRIDGE, Mass., Aug. 6, 2019 /PRNewswire/ – Leap Therapeutics, Inc. (NASDAQ: LPTX) today announced that its anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with Merck’s anti-PD-1 antibody, Keytruda® (pembrolizumab), demonstrated higher survival and objective response outcomes in patients with advanced gastroesophageal junction and gastric cancer (GEJ/GC) whose tumors expressed high levels of DKK1 (DKK1-high).  DKN-01 plus Keytruda therapy achieved over 22 weeks median progression-free survival (PFS) and nearly 32…

Early detection of HPV can prevent various forms of cancer in both men and women, including gay, transgender, and HIV-positive patients   PASADENA, Calif (August 6, 2019) – OmniPathology (www.omnipathology.com), a physician-owned medical laboratory specializing in state-of-the-art pathology services, today announced its new FISH (fluorescence in situ hybridization) test to detect human papillomavirus (HPV) related cancer in patients. What makes the test unique is that it is more accurate than other means used to detect HPV-related changes. The test has already been used to identify patients who otherwise would go untreated.   The new OmniPathology FISH test uses advanced fluorescence…

Twitter

Earn CME: https://naccme.com/program/7334 In this presentation from the ‘Keeping Up With CAR T-cell Therapies in B-Cell Lymphomas’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Matthew J. Frigault discusses best practices for the management of cytokine release syndrome (CRS) and neurotoxicity when utilizing CAR-T therapy. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/7333 In this presentation from the ‘Persistent Challenges in the Management of Follicular Lymphoma’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Elizabeth Brem provides and update on the treatment of relapsed/refractory follicular lymphoma. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7333 In this presentation from the ‘Persistent Challenges in the Management of Follicular Lymphoma’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. John P. Leonard provides an update on upfront and maintenance therapy advances in the treatment of follicular lymphoma. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7334 In this presentation from the ‘Keeping Up With CAR T-cell Therapies in B-Cell Lymphomas’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Caron A. Jacobson discusses the current state of CAR-T therapy in the treatment of lymphoma. © 2019 Imedex, an HMP Company

Earn CME: https://www.naccme.com/program/7332 In this presentation from the ‘Confronting the Challenges of Peripheral T-Cell Lymphoma: Genomic Profiling and the Future Treatment Landscape symposium at the 2019 Great Debates and Updates in Hematologic Malignancies, Dr. Jasmine Zain discusses novel therapies and future targets for the treatment of peripheral t-cell lymphoma. © 2019 Imedex, an HMP Company

July 2, 2019 San Diego Supercomputer Center Researchers Find Novel Diagnosis Method    The invasive and expensive diagnosis process of bladder cancer, which is one of the most common and aggressive cancers in the United States, may be soon helped by a novel non-invasive diagnostic method thanks to advances in machine learning research at the San Diego Supercomputer Center (SDSC), Moores Cancer Center, and CureMatch Incorporated.   Research scientists Igor Tsigelny and Valentina Kouznetsova have been working on the development of a machine-learning (ML) model that looks at a patient’s metabolites and their chemical descriptors. The model accurately classifies the…

Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains how the landscape is changing in treating metastatic hormone-sensitive prostate cancer.